Merck & Company Inc (MRK)

78.33
0.00(0.00%)
After Hours
78.33
0.00(0.00%)
- Real-time Data
  • Volume:
    12,855,253
  • Bid/Ask:
    78.33/78.68
  • Day's Range:
    77.98 - 79.06

MRK Overview

Prev. Close
78.33
Day's Range
77.98-79.06
Revenue
47.1B
Open
78.2
52 wk Range
68.38-84.56
EPS
1.89
Volume
12,855,253
Market Cap
198.28B
Dividend (Yield)
2.60
(3.32%)
Average Volume (3m)
13,075,557
P/E Ratio
41.46
Beta
0.41
1-Year Change
2.9%
Shares Outstanding
2,531,374,696
Next Earnings Date
27 Oct 2021
What is your sentiment on Merck & Company Inc?
or
Market is currently closed. Voting is open during market hours.

Merck & Company Inc News

Merck & Company Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyNeutralSellBuyStrong Buy
Technical IndicatorsStrong BuyStrong BuyStrong SellStrong SellBuy
SummaryStrong BuyBuyStrong SellNeutralStrong Buy

Merck & Company Inc Company Profile

Merck & Company Inc Company Profile

Employees
74000

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women’s health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology and autoimmunity (intestinal epithelial barrier in autoimmune diseases); NGM Biopharmaceuticals, Inc. to focus primarily on the development of medicines in retinal and CVM diseases; and to develop and commercialize tests that identify genetic mutations, as well as with IO Biotech ApS to evaluate IO102-IO103. It also has a partnership with Biocorp Production for the development and supply of a specific version of Mallya device. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.